AGL 40.00 Decreased By ▼ -0.16 (-0.4%)
AIRLINK 129.53 Decreased By ▼ -2.20 (-1.67%)
BOP 6.68 Decreased By ▼ -0.01 (-0.15%)
CNERGY 4.63 Increased By ▲ 0.16 (3.58%)
DCL 8.94 Increased By ▲ 0.12 (1.36%)
DFML 41.69 Increased By ▲ 1.08 (2.66%)
DGKC 83.77 Decreased By ▼ -0.31 (-0.37%)
FCCL 32.77 Increased By ▲ 0.43 (1.33%)
FFBL 75.47 Increased By ▲ 6.86 (10%)
FFL 11.47 Increased By ▲ 0.12 (1.06%)
HUBC 110.55 Decreased By ▼ -1.21 (-1.08%)
HUMNL 14.56 Increased By ▲ 0.25 (1.75%)
KEL 5.39 Increased By ▲ 0.17 (3.26%)
KOSM 8.40 Decreased By ▼ -0.58 (-6.46%)
MLCF 39.79 Increased By ▲ 0.36 (0.91%)
NBP 60.29 No Change ▼ 0.00 (0%)
OGDC 199.66 Increased By ▲ 4.72 (2.42%)
PAEL 26.65 Decreased By ▼ -0.04 (-0.15%)
PIBTL 7.66 Increased By ▲ 0.18 (2.41%)
PPL 157.92 Increased By ▲ 2.15 (1.38%)
PRL 26.73 Increased By ▲ 0.05 (0.19%)
PTC 18.46 Increased By ▲ 0.16 (0.87%)
SEARL 82.44 Decreased By ▼ -0.58 (-0.7%)
TELE 8.31 Increased By ▲ 0.08 (0.97%)
TOMCL 34.51 Decreased By ▼ -0.04 (-0.12%)
TPLP 9.06 Increased By ▲ 0.25 (2.84%)
TREET 17.47 Increased By ▲ 0.77 (4.61%)
TRG 61.32 Decreased By ▼ -1.13 (-1.81%)
UNITY 27.43 Decreased By ▼ -0.01 (-0.04%)
WTL 1.38 Increased By ▲ 0.10 (7.81%)
BR100 10,407 Increased By 220 (2.16%)
BR30 31,713 Increased By 377.1 (1.2%)
KSE100 97,328 Increased By 1781.9 (1.86%)
KSE30 30,192 Increased By 614.4 (2.08%)

Death rates from prostate cancer - the most commonly diagnosed cancer in men - have stabilized or declined in dozens of countries since the turn of the century, the American Cancer Society reported on Tuesday.
In 33 of 44 countries surveyed, the incidence of prostate cancer had stabilized in the last five years for which data was available - and in seven countries, it was down, the report found. Only four of the countries surveyed, including Bulgaria, saw an increased incidence of prostate cancer, it said.
"In the most recent five years of data examined, prostate cancer incidence and mortality rates are decreasing or stabilizing in most parts of the world," the study's author MaryBeth Freeman said. Prostate cancer deaths were down in 14 countries surveyed and stable in 54 others. Only three countries experienced a rise in prostate cancer deaths, according to the study findings, which were presented on Tuesday at a conference in Atlanta.
The United States had the biggest drop in prostate cancers, which Freeman attributed to a decline in the use of a controversial diagnostic test that identified too many non-dangerous tumors. The incidence of prostate cancers rose in the US during the 1980s and early 1990s when the PSA, or Prostate-Specific Antigen, blood test became widely available.
The test is imprecise, however, and yields too many false positives. It identifies higher than normal levels of PSA, a protein produced by the prostate, which could be a sign of cancer but is more often a symptom of other diseases.
Moreover, some prostate cancers are not aggressive and do not grow enough to pose a risk.
A false positive, on the other hand, can have harmful consequences for the patient: anxiety, complications linked to biopsies or anti-cancer treatments.
In 2012, the US Preventive Services Task Force, an expert panel that reviews the effectiveness of preventive clinical services, advised against use of the PSA test.

Copyright Agence France-Presse, 2019

Comments

Comments are closed.